GE HealthCare and Novo Nordisk collaborate on ultrasound solutions

GE HealthCare and Novo Nordisk Collaborate on Peripheral-Focused Ultrasound (PFUS) for Diabetes and Obesity

GE HealthCare and Novo Nordisk, a renowned Danish pharmaceutical company, have joined forces to enhance the development of PFUS as a non-invasive treatment option for type 2 diabetes and obesity.

PFUS utilizes ultrasound to stimulate the nervous system, potentially triggering therapeutic responses. Preliminary studies indicate its potential to regulate glucose metabolism in diabetic individuals through customized ultrasound stimulation of nerve pathways.

This collaboration leverages GE HealthCare’s expertise in ultrasound medical technology and Novo Nordisk’s deep understanding of metabolic disease management. Together, they aim to create an innovative PFUS solution that optimizes patient outcomes.

The partnership builds upon GE HealthCare’s pioneering research in PFUS. The companies will combine their knowledge and resources to advance the technology and its clinical applications.

Details of the agreement, including financial terms, remain confidential.